** Shares of Emyria EMD.AX rise 2.9% to A$0.036, their highest levels since Dec 11
** The early-stage drug developer announces positive interim analysis results of its MDMA-assisted therapy programme for Post Traumatic Stress Disorder (PTSD)
** Co says therapy programme clinically reduces PTSD symptoms in first eight patients
** Stock rose as much as 14.3% to A$0.040 earlier in the day, marking its biggest intraday gain since Jan 22
** About 1.3 mln shares change hands, 6.9 times the 30-day average of 189,038
** Stock has risen 5.9% YTD, including current session's moves
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。